ReviewVascular health and risk management2015
Breast cancer therapy and cardiovascular risk: focus on trastuzumab.
Review in Vascular health and risk management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Anthracyclines-Induced Vascular Endothelial Dysfunction in Cancer Patients and Survivors Using Brachial Flow-Mediated Dilation (FMD) Tool: A Systematic Review and Meta-Analysis.Cardiovascular toxicology · 2025Pooled it
- Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients.Cancer reports (Hoboken, N.J.) · 2025Article
- Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment.Life (Basel, Switzerland) · 2025Review
- Troponin Elevation in Asymptomatic Cancer Patients: Unveiling Connections and Clinical Implications.Current heart failure reports · 2024Review
- Article
- FBXO3 stabilizes USP4 and Twist1 to promote PI3K-mediated breast cancer metastasis.PLoS biology · 2023Article
- Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery.Frontiers in cardiovascular medicine · 2023Review
- Two-dimensional speckle tracking echocardiography help identify breast cancer therapeutics-related cardiac dysfunction.BMC cardiovascular disorders · 2022Article
- Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress.American journal of physiology. Heart and circulatory physiology · 2022Review
- Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.Breast cancer research and treatment · 2021Review
- Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer.International journal of molecular medicine · 2019Article
- Knockdown of lncRNA HOTAIR sensitizes breast cancer cells to ionizing radiation through activating miR-218.Bioscience reports · 2019Article
- Biological agents in gastrointestinal cancers: adverse effects and their management.Journal of gastrointestinal oncology · 2017Review
- Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application.International journal of molecular sciences · 2017Article
- TNF-α sensitizes chemotherapy and radiotherapy against breast cancer cells.Cancer cell international · 2017Article
- Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Exercise training improves cardiopulmonary and endothelial function in women with breast cancer: findings from the Diana-5 study.Internal and emergency medicine · 2016Article
- Sex-Specific Physiology and Cardiovascular Disease.Advances in experimental medicine and biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common cancer in the UK. Advances in the methods of early diagnosis as well as newer and more effective treatments have led to improvements of disease-free and overall survival over the last decade. Almost one-third of breast cancers present with an aggressive form characterized by increased expression of human epidermal growth receptor 2 (HER2) proteins. A targeted treatment using monoclonal antibodies against HER2 expression such as trastuzumab has been shown to improve survival. Unfortunately, there is a degree of cardiotoxicity associated with these agents, as inhibition of HER2 pathways can also impair cardioprotective pathways. In the present review, we discuss the mechanisms by which trastuzumab might affect vascular homeostasis leading to endothelial dysfunction. We also provide suggestions for future research examining the effects of trastuzumab on the vasculature in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.